Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug formulation containing **loxoprofen** (a nonsteroidal anti-inflammatory drug, NSAID), **allyl isopropylacetyl urea** (a sedative-hypnotic, also known as apronalide or apronal), and **anhydrous caffeine** (a central nervous system stimulant)[6]. Loxoprofen acts as a prodrug that is metabolized to an active form, functioning as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), leading to analgesic, anti-inflammatory, and antipyretic effects[6][7][8]. Allyl isopropylacetyl urea is used for its mild sedative and hypnotic actions. Anhydrous caffeine enhances the analgesic effect and provides mild CNS stimulation[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loxoprofen + allyl isopropylacetyl urea + anhydrous caffeine.